PMID- 33529909
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 93
DP  - 2021 Apr
TI  - IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic 
      hepatitis C patients before and after antiviral treatment.
PG  - 107405
LID - S1567-5769(21)00041-2 [pii]
LID - 10.1016/j.intimp.2021.107405 [doi]
AB  - Few studies on the immunoglobulin E (IgE) immune response in chronic hepatitis C 
      have been reported. In this study, we tested the antigenicity of commercial 
      recombinant hepatitis C virus (HCV) core and nonstructural protein NS3, NS4, and 
      NS5 antigens and the IgE immune response to these antigens in chronic hepatitis C 
      patients before and after antiviral treatment with pegylated interferon (IFN)-alpha 
      plus ribavirin for 12 weeks. The effects of antiviral treatment were investigated 
      in 20 out of 35 participants. We developed amplified immunoassays using these 
      antigens and IgG-depleted patient sera. Seropositivity for IgE antibodies was 
      determined, and serum IgE and cytokine levels were measured. Anti-core, anti-NS3, 
      and anti-NS4 IgE antibodies were observed in most patients, whereas anti-NS5 
      antibodies were less prevalent. Antiviral treatment decreased the production of 
      anti-core, anti-NS3, and anti-NS4 IgE antibodies, but not anti-NS5 IgE 
      antibodies. A significant decrease in the anti-NS3 and anti-NS4 IgE antibody 
      levels was observed in patients who presented with an early sustained virological 
      response, but no effects on anti-core and anti-NS5 IgE antibodies was observed. 
      The serum levels of IFN-gamma, interleukin (IL)-2, IL-6, tumor necrosis factor-alpha, and 
      IL-10, but not IL-4, were similar between patients before and after antiviral 
      therapy. Thus, the immune response of IgE antibodies to HCV antigens was 
      comparable to that of anti-HCV IgG antibodies. The usefulness of anti-NS3 IgE 
      antibodies in diagnosing occult hepatitis C and monitoring antiviral treatment 
      with directly acting antiviral medication must be investigated in future studies.
CI  - Copyright (c) 2021. Published by Elsevier B.V.
FAU - Silva, Joao Paulo C G
AU  - Silva JPCG
AD  - Programa de Pos-Graduacao em Imunologia, Instituto de Ciencias da Saude, 
      Universidade Federal da Bahia, Salvador, BA, Brazil.
FAU - Jesus, Larissa S
AU  - Jesus LS
AD  - Programa de Pos-Graduacao em Farmacia, Faculdade de Farmacia, Universidade 
      Federal da Bahia, Salvador, BA, Brazil.
FAU - Isabel Schinoni, Maria
AU  - Isabel Schinoni M
AD  - Servico de Hepatites, Hospital Professor Edgard Santos, Faculdade de Medicina, 
      Universidade Federal da Bahia, Salvador, BA, Brazil.
FAU - Oliveira, Isabela S
AU  - Oliveira IS
AD  - Laboratorio de Pesquisa em Imunologia, Faculdade de Farmacia, Universidade 
      Federal da Bahia, Salvador, BA, Brazil.
FAU - Atta, Maria Luiza B S
AU  - Atta MLBS
AD  - Laboratorio de Pesquisa em Imunologia, Faculdade de Farmacia, Universidade 
      Federal da Bahia, Salvador, BA, Brazil.
FAU - Atta, Ajax M
AU  - Atta AM
AD  - Laboratorio de Pesquisa em Imunologia, Faculdade de Farmacia, Universidade 
      Federal da Bahia, Salvador, BA, Brazil. Electronic address: ajaxmatta@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20210130
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Viral Core Proteins)
RN  - 0 (Viral Nonstructural Proteins)
RN  - 0 (nucleocapsid protein, Hepatitis C virus)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Viral/blood
MH  - Antiviral Agents/*therapeutic use
MH  - Female
MH  - Hepacivirus/*physiology
MH  - Hepatitis C, Chronic/*drug therapy/immunology
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/*therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/*therapeutic use
MH  - Viral Core Proteins/*immunology
MH  - Viral Nonstructural Proteins/*immunology
OTO - NOTNLM
OT  - Antiviral treatment
OT  - Cytokine
OT  - HCV antigen
OT  - Hepatitis C
OT  - IgE antibody
EDAT- 2021/02/03 06:00
MHDA- 2021/05/29 06:00
CRDT- 2021/02/02 20:12
PHST- 2020/09/17 00:00 [received]
PHST- 2021/01/09 00:00 [revised]
PHST- 2021/01/13 00:00 [accepted]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2021/02/02 20:12 [entrez]
AID - S1567-5769(21)00041-2 [pii]
AID - 10.1016/j.intimp.2021.107405 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Apr;93:107405. doi: 10.1016/j.intimp.2021.107405. Epub 
      2021 Jan 30.